PRNewsWire
21 May 2026, 19:45 UTC · 2h ago
Source · https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-grace-therapeutics-inc---grce-302779453.html
Read source
Story key points
3 claims · impact-rated
The FDA issued a Complete Response Letter (CRL) rejecting the New Drug Application for Grace Therapeutics' GTx-104 due to manufacturing deficiencies and toxicology risks. — A CRL is a major regulatory setback that prevents a drug from reaching the market, directly impacting future revenue and company valuation.
-0.90Pomerantz LLP is investigating Grace Therapeutics for potential securities fraud and unlawful business practices following the FDA's action. — The initiation of a class action investigation creates additional legal liability and suggests potential mismanagement or lack of transparency.
-0.40Grace Therapeutics' stock price fell approximately 45.48% to $2.35 per share immediately following the FDA announcement. — While the price drop has already occurred, this confirms a massive loss of market confidence and sets a lower baseline for the asset.
-0.20Impact vectors
Search tags
6 dimensions · 9 clusters
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Ticker attribution
Model heads
The company received an FDA Complete Response Letter, suffered a 45% stock price crash, and is under investigation for securities fraud.
The company is being investigated by a law firm on behalf of investors regarding potential claims.
The company is being investigated by a law firm on behalf of investors regarding potential claims.
No ticker relationship head found.
